219A

�ｼｨ�ｽ��ｽ��ｽ抵ｽ費ｽ難ｽ��ｽ��ｽ�譬ｪ蠑丈ｼ夂､ｾ

Ｈｅａｒｔｓｅｅｄ株式会社
Pharmaceutical
Heartseed Inc. develops and commercializes iPS cell-derived cardiomyocyte replacement therapy for heart failure. The company's lead product is HS-001 for heart failure with reduced ejection fraction indications, including dilated cardiomyopathy, old myocardial infraction, and dilated phase of hypertrophic cardiomyopathy. It also develops products using autologous iPSC and HLA knock-out iPSC. In addition, the company offers differentiation induction, mass culture, purification, and myocardial globule production technology. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.
← Companies
Price
¥1,542
Market Cap
¥35.2B
Ent. Value
—
Net Cash est
—
Shares Out.
22.9M
P / E
182.7×
EV / EBIT
—
P / Book
4.90×
P / NCAV
5.29×
Div. Yield
—
Financials
Metric FY 2025
EDINET ↗ 		FY 2024
EDINET ↗
Net Sales ¥3.0B ¥874M
Gross Profit ¥3.0B ¥874M
SG&A ¥2.8B ¥1.9B
Operating Income ¥272M ¥-1.0B
Non-Operating Income ¥59M ¥262M
Interest Income ¥6M ¥0M
Non-Operating Expenses ¥42M ¥42M
Interest Expense ¥0M ¥0M
Ordinary Income ¥289M ¥-819M
Pre-tax Income ¥289M ¥-819M
Income Taxes ¥98M ¥-6M
Current Tax ¥102M ¥5M
Deferred Tax ¥-3M ¥-11M
Net Income (owners) ¥191M ¥-813M
EBITDA ¥325M ¥-997M
EPS ¥8.44 ¥-49.43
Shares Outstanding 22.9M 22.2M
Shares Issued (total) 22.9M 22.2M